QQQ   289.58 (-0.54%)
AAPL   137.35 (-2.46%)
MSFT   253.14 (-0.37%)
FB   191.29 (-0.49%)
GOOGL   2,207.68 (-1.35%)
AMZN   2,146.38 (+0.19%)
TSLA   709.42 (-0.05%)
NVDA   171.24 (+1.10%)
BABA   87.69 (+0.44%)
NIO   16.66 (+5.24%)
AMD   96.67 (+0.41%)
CGC   5.87 (+5.01%)
MU   69.40 (-2.32%)
T   20.21 (-0.10%)
GE   75.74 (+0.72%)
F   12.85 (+0.55%)
DIS   103.14 (-1.11%)
AMC   13.08 (+2.51%)
PFE   50.65 (+0.50%)
PYPL   81.28 (+5.31%)
NFLX   183.48 (+3.55%)
QQQ   289.58 (-0.54%)
AAPL   137.35 (-2.46%)
MSFT   253.14 (-0.37%)
FB   191.29 (-0.49%)
GOOGL   2,207.68 (-1.35%)
AMZN   2,146.38 (+0.19%)
TSLA   709.42 (-0.05%)
NVDA   171.24 (+1.10%)
BABA   87.69 (+0.44%)
NIO   16.66 (+5.24%)
AMD   96.67 (+0.41%)
CGC   5.87 (+5.01%)
MU   69.40 (-2.32%)
T   20.21 (-0.10%)
GE   75.74 (+0.72%)
F   12.85 (+0.55%)
DIS   103.14 (-1.11%)
AMC   13.08 (+2.51%)
PFE   50.65 (+0.50%)
PYPL   81.28 (+5.31%)
NFLX   183.48 (+3.55%)
QQQ   289.58 (-0.54%)
AAPL   137.35 (-2.46%)
MSFT   253.14 (-0.37%)
FB   191.29 (-0.49%)
GOOGL   2,207.68 (-1.35%)
AMZN   2,146.38 (+0.19%)
TSLA   709.42 (-0.05%)
NVDA   171.24 (+1.10%)
BABA   87.69 (+0.44%)
NIO   16.66 (+5.24%)
AMD   96.67 (+0.41%)
CGC   5.87 (+5.01%)
MU   69.40 (-2.32%)
T   20.21 (-0.10%)
GE   75.74 (+0.72%)
F   12.85 (+0.55%)
DIS   103.14 (-1.11%)
AMC   13.08 (+2.51%)
PFE   50.65 (+0.50%)
PYPL   81.28 (+5.31%)
NFLX   183.48 (+3.55%)
QQQ   289.58 (-0.54%)
AAPL   137.35 (-2.46%)
MSFT   253.14 (-0.37%)
FB   191.29 (-0.49%)
GOOGL   2,207.68 (-1.35%)
AMZN   2,146.38 (+0.19%)
TSLA   709.42 (-0.05%)
NVDA   171.24 (+1.10%)
BABA   87.69 (+0.44%)
NIO   16.66 (+5.24%)
AMD   96.67 (+0.41%)
CGC   5.87 (+5.01%)
MU   69.40 (-2.32%)
T   20.21 (-0.10%)
GE   75.74 (+0.72%)
F   12.85 (+0.55%)
DIS   103.14 (-1.11%)
AMC   13.08 (+2.51%)
PFE   50.65 (+0.50%)
PYPL   81.28 (+5.31%)
NFLX   183.48 (+3.55%)
NASDAQ:VRCA

Verrica Pharmaceuticals (VRCA) Stock Forecast, Price & News

$5.92
-0.17 (-2.79%)
(As of 05/19/2022 04:00 PM ET)
Add
Compare
Today's Range
$5.88
$6.16
50-Day Range
$5.42
$8.93
52-Week Range
$5.20
$14.79
Volume
195,494 shs
Average Volume
84,600 shs
Market Capitalization
$162.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.96
30 days | 90 days | 365 days | Advanced Chart
Receive VRCA News and Ratings via Email

Sign-up to receive the latest news and ratings for Verrica Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Verrica Pharmaceuticals logo

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VRCA
Fax
N/A
Employees
38
Year Founded
N/A

Sales & Book Value

Annual Sales
$12 million
Book Value
$0.92 per share

Profitability

Net Income
$-35.08 million
Pretax Margin
-9,887.24%

Debt

Price-To-Earnings

Miscellaneous

Free Float
16,456,000
Market Cap
$162.91 million
Optionable
Not Optionable

Company Calendar

Last Earnings
3/02/2022
Today
5/19/2022
Next Earnings (Estimated)
8/09/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.01 out of 5 stars

Medical Sector

579th out of 1,418 stocks

Pharmaceutical Preparations Industry

264th out of 677 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -













Verrica Pharmaceuticals (NASDAQ:VRCA) Frequently Asked Questions

Is Verrica Pharmaceuticals a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Verrica Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Verrica Pharmaceuticals stock.
View analyst ratings for Verrica Pharmaceuticals
or view top-rated stocks.

When is Verrica Pharmaceuticals' next earnings date?

Verrica Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for Verrica Pharmaceuticals
.

How were Verrica Pharmaceuticals' earnings last quarter?

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) announced its earnings results on Wednesday, March, 2nd. The company reported ($0.35) earnings per share for the quarter, topping analysts' consensus estimates of ($0.48) by $0.13.
View Verrica Pharmaceuticals' earnings history
.

What price target have analysts set for VRCA?

7 analysts have issued 1 year target prices for Verrica Pharmaceuticals' stock. Their forecasts range from $16.00 to $20.00. On average, they anticipate Verrica Pharmaceuticals' stock price to reach $18.67 in the next year. This suggests a possible upside of 215.3% from the stock's current price.
View analysts' price targets for Verrica Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Verrica Pharmaceuticals' key executives?
Verrica Pharmaceuticals' management team includes the following people:
  • Mr. Ted White, Pres, CEO & Director (Age 57, Pay $725.85k) (LinkedIn Profile)
  • Dr. Gary Goldenberg M.D., Chief Medical Officer (Age 45, Pay $571.57k)
  • Mr. P. Terence Kohler, Chief Financial Officer
  • Mr. Christopher G. Hayes, Chief Legal Officer, Sec., Chief Compliance Officer & Gen. Counsel (Age 58) (LinkedIn Profile)
  • Mr. Joe Bonaccorso, Chief Commercial Officer (Age 58)
  • Mr. Eugene Scavola, Exec. VP of Technical Operations
  • Dr. Bradley J. Catalone MBA, Ph.D., Head of Drug Devel.
What other stocks do shareholders of Verrica Pharmaceuticals own?
When did Verrica Pharmaceuticals IPO?

(VRCA) raised $75 million in an initial public offering (IPO) on Friday, June 15th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen served as the underwriters for the IPO.

What is Verrica Pharmaceuticals' stock symbol?

Verrica Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRCA."

Who are Verrica Pharmaceuticals' major shareholders?

Verrica Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.83%), State Street Corp (0.84%), Northern Trust Corp (0.49%), Dimensional Fund Advisors LP (0.12%), Truist Financial Corp (0.04%) and Goldman Sachs Group Inc. (0.04%). Company insiders that own Verrica Pharmaceuticals stock include A Brian Davis, Christopher G Hayes, Craig Ballaron, Paul B Manning, Paul B Manning and Ted White.
View institutional ownership trends for Verrica Pharmaceuticals
.

Which institutional investors are selling Verrica Pharmaceuticals stock?

VRCA stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., BlackRock Inc., Northern Trust Corp, and Royal Bank of Canada.
View insider buying and selling activity for Verrica Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Verrica Pharmaceuticals stock?

VRCA stock was purchased by a variety of institutional investors in the last quarter, including Truist Financial Corp, Goldman Sachs Group Inc., Dimensional Fund Advisors LP, and State Street Corp. Company insiders that have bought Verrica Pharmaceuticals stock in the last two years include A Brian Davis, Christopher G Hayes, Craig Ballaron, Paul B Manning, and Ted White.
View insider buying and selling activity for Verrica Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Verrica Pharmaceuticals?

Shares of VRCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Verrica Pharmaceuticals' stock price today?

One share of VRCA stock can currently be purchased for approximately $5.92.

How much money does Verrica Pharmaceuticals make?

Verrica Pharmaceuticals has a market capitalization of $162.91 million and generates $12 million in revenue each year. The company earns $-35.08 million in net income (profit) each year or ($1.56) on an earnings per share basis.

How many employees does Verrica Pharmaceuticals have?

Verrica Pharmaceuticals employs 38 workers across the globe.

What is Verrica Pharmaceuticals' official website?

The official website for Verrica Pharmaceuticals is www.verrica.com.

How can I contact Verrica Pharmaceuticals?

Verrica Pharmaceuticals' mailing address is 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380. The company can be reached via phone at (434) 453-3300 or via email at [email protected].

This page was last updated on 5/19/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.